Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study.
Tie ZhouFangjian ZhouJianming GuoHongcheng ShiXudong YaoHongqian GuoJian YuanYe TianXiaodong ZhangShuxia WangYongguang JiangQing ZouDaqing ZhouHanzhong LiFang LiJae Lyun LeeChung-Hsin ChenSe Hoon ParkQuan Sing NgJianhui MaRong ZhengQiang DingXingdang LiuRui LiHeiko KrisselVolker J WagnerYinghao SunPublished in: Asia-Pacific journal of clinical oncology (2020)
The results of this study support the use of the standard radium-223 regimen for the treatment of Asian patients with castrate-resistant prostate cancer and symptomatic bone metastases.